[go: up one dir, main page]

TR200201150T2 - Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod. - Google Patents

Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.

Info

Publication number
TR200201150T2
TR200201150T2 TR2002/01150T TR200201150T TR200201150T2 TR 200201150 T2 TR200201150 T2 TR 200201150T2 TR 2002/01150 T TR2002/01150 T TR 2002/01150T TR 200201150 T TR200201150 T TR 200201150T TR 200201150 T2 TR200201150 T2 TR 200201150T2
Authority
TR
Turkey
Prior art keywords
inhibitor
phosphodiesterase
administering
rate
administered
Prior art date
Application number
TR2002/01150T
Other languages
English (en)
Inventor
D. Murdoch Robert
J. Torphy Theodore
D. Zussman Barry
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of TR200201150T2 publication Critical patent/TR200201150T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Bu bulus, tek bir defada uygulanabilen ve inhibitörün plazma konsantrasyonunda yükselme hizini veya abzorpsiyon hizini düsürmek suretiyle hasta tarafindan iyi tolere edilebilen, bir PDE4 inhibitörü dozunun yükseltilmesine yönelik bir metod ile ilgilidir.
TR2002/01150T 1999-10-29 2000-10-26 Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod. TR200201150T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16247799P 1999-10-29 1999-10-29
US16264199P 1999-11-01 1999-11-01
US17981700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
TR200201150T2 true TR200201150T2 (tr) 2002-09-23

Family

ID=27388757

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01150T TR200201150T2 (tr) 1999-10-29 2000-10-26 Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.

Country Status (29)

Country Link
US (1) US20030212112A1 (tr)
EP (1) EP1225884A4 (tr)
JP (1) JP2003513038A (tr)
KR (1) KR20020050249A (tr)
CN (1) CN1387433A (tr)
AP (1) AP2002002446A0 (tr)
AR (1) AR026254A1 (tr)
AU (1) AU772909B2 (tr)
BG (1) BG106623A (tr)
BR (1) BR0015039A (tr)
CA (1) CA2389293A1 (tr)
CO (1) CO5271676A1 (tr)
CZ (1) CZ20021443A3 (tr)
DZ (1) DZ3249A1 (tr)
EA (1) EA200200502A1 (tr)
HK (1) HK1049105A1 (tr)
HU (1) HUP0203682A3 (tr)
IL (1) IL148813A0 (tr)
MA (1) MA25562A1 (tr)
MX (1) MXPA02004220A (tr)
NO (1) NO20021937L (tr)
NZ (1) NZ518002A (tr)
OA (1) OA12078A (tr)
PE (1) PE20011004A1 (tr)
PL (1) PL355262A1 (tr)
SK (1) SK7292002A3 (tr)
TR (1) TR200201150T2 (tr)
UY (1) UY26422A1 (tr)
WO (1) WO2001032165A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
HRP20050399B1 (hr) 2003-03-10 2013-09-30 Takeda Gmbh Novi postupci za dobivanje roflumilasta
US20060239927A1 (en) * 2003-03-31 2006-10-26 Kyowa Hakko Kogyo Co., Drug for airway administration
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
RU2576033C2 (ru) * 2009-12-03 2016-02-27 Опко Хелс, Инк. Составы на основе гиперсулфатированных дисахаридов
SMT202000339T1 (it) * 2011-12-27 2020-07-08 Amgen Europe Gmbh FORMULAZIONI DI (+)-2-[1-(3-ETOSSl-4-METOSSI-FENIL)-2-METANSOLFONIL-ETIL]-4-ACETILAMMINOISOINDOLIN-1,3-DIONE
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

Also Published As

Publication number Publication date
BG106623A (bg) 2003-02-28
DZ3249A1 (fr) 2001-05-10
OA12078A (en) 2003-05-28
EP1225884A4 (en) 2005-06-15
NO20021937D0 (no) 2002-04-24
AP2002002446A0 (en) 2002-03-31
CO5271676A1 (es) 2003-04-30
HK1049105A1 (zh) 2003-05-02
CN1387433A (zh) 2002-12-25
MXPA02004220A (es) 2002-10-17
HUP0203682A3 (en) 2003-10-28
AR026254A1 (es) 2003-02-05
EA200200502A1 (ru) 2002-10-31
NO20021937L (no) 2002-05-30
PL355262A1 (en) 2004-04-05
HUP0203682A2 (hu) 2003-04-28
JP2003513038A (ja) 2003-04-08
UY26422A1 (es) 2001-07-31
NZ518002A (en) 2004-01-30
BR0015039A (pt) 2002-06-25
CA2389293A1 (en) 2001-05-10
SK7292002A3 (en) 2002-12-03
EP1225884A1 (en) 2002-07-31
US20030212112A1 (en) 2003-11-13
IL148813A0 (en) 2002-09-12
PE20011004A1 (es) 2001-09-28
CZ20021443A3 (cs) 2003-01-15
KR20020050249A (ko) 2002-06-26
WO2001032165A1 (en) 2001-05-10
AU772909B2 (en) 2004-05-13
AU1344501A (en) 2001-05-14
MA25562A1 (fr) 2002-10-01

Similar Documents

Publication Publication Date Title
TR200201150T2 (tr) Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
DE69618231D1 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
EP1510221A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
BR9808221A (pt) Método de tratamento de tumor.
DE69821498D1 (de) Verwendung von amifostin
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
SE0004827D0 (sv) Therapeutic compounds
TR200202033T2 (tr) Epilepsi Tedavisi İçin Terkipler ve Yöntemler
DK1244442T3 (da) Fremgangsmåde til bestemmelse af nukleotidsynteseinhibitorer med færre bivirkninger
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO2003066806A3 (en) Therapeutic use of aziridino compounds
WO2004004643A3 (en) Interferon gamma in the detection and treatment of angiomyolipomas